Ascendiant Maintains Myomo(MYO.US) With Buy Rating, Raises Target Price to $9
Myomo Is Maintained at Buy by Ascendiant Capital
Myomo Price Target Raised to $9.00/Share From $8.50 by Ascendiant Capital
Myomo Analyst Ratings
Maxim Group Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Lake Street Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $7.5
Analysts Offer Insights on Healthcare Companies: Petmed Express (PETS), Myomo (MYO) and Accuray (ARAY)
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Lake Street Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $7.5
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Lake Street Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $7.5
Lake Street Keeps Their Buy Rating on Myomo (MYO)
Craig-Hallum Initiates Myomo(MYO.US) With Buy Rating
Myomo Analyst Ratings
Myomo Analyst Ratings
Myomo Inc.: Strong Performance and Growth Prospects Justify Buy Rating
No Data
No Data